<DOC>
	<DOCNO>NCT01476657</DOCNO>
	<brief_summary>The purpose study determine safety , maximum tolerate dose pharmacokinetics IPI-145 patient advance hematologic malignancy .</brief_summary>
	<brief_title>A Phase 1 Study Duvelisib Patients With Advanced Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>≥ 18 year age ; Progressed , refractory , intolerant , ineligible establish therapy , disease establish therapy exception expansion cohort treatment naïve CLL patient ; An Eastern Cooperative Oncology Group ( ECOG ) score 0 2 . Any previous treatment PI3K inhibitor ( Escalation Phase ) within 4 week start IPI145 administration ( Expansion Phase ) ; Patients overt leptomeningeal leukemia CNS lymphoma ; Inadequate hepatic function define aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2.5 x upper limit normal ( ULN ) ; direct bilirubin &gt; 1.5 x ULN ; Inadequate renal function define serum creatinine &gt; 1.5 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Phase 1</keyword>
</DOC>